Mammary Analogue Secretory Carcinoma of Salivary Gland Origin: An Update and Expanded Morphologic and Immunohistochemical Spectrum of Recently Described Entity

被引：108

作者：

Skalova A. ^{[1
]}

机构：

[1] Sikl's Department of Pathology, Faculty of Medicine in Pilsen, Faculty Hospital, Medical Faculty of Charles University, 305 99 Plzen

来源：

Head and Neck Pathology | 2013年 / 7卷 / Suppl 1期

关键词：

ETV6-NTRK3; fusion; Mammary analogue secretory carcinoma; MASC; Salivary gland;

D O I：

10.1007/s12105-013-0455-y

中图分类号：

学科分类号：

摘要：

Mammary analogue secretory carcinoma of salivary gland origin (MASC) is a recently described tumor with ETV6 translocation. Akin to secretory breast cancer, MASC expresses S-100 protein, mammaglobin, vimentin, and harbors a t(12;15) (p13;q25) translocation which leads to ETV6-NTRK3 fusion product. Histologically, MASC displays a lobulated growth pattern and is often composed of microcystic, tubular, and solid structures with abundant eosinophilic homogeneous or bubbly secretions. Colloid-like secretory material stains positive for periodic acid-Schiff (PAS) with and without diastase and for Alcian blue. The cells of MASC are devoid of PAS-positive secretory zymogen granules. These features help to exclude the most important differential diagnostic considerations, namely acinic cell carcinoma, low-grade cribriform cystadenocarcinoma, cystadenocarcinoma (not otherwise specified), and low-grade mucoepidermoid carcinoma. To date the presence of the ETV6-NTRK3 fusion gene has not been demonstrated in any other salivary gland tumor than MASC. It is likely that MASC is more common than currently recognized and with further studies, the clinical need for molecular studies of the ETV6-NTRK3 fusion may diminish. However, molecular testing is recommended at this time to arrive at the diagnosis of MASC. © 2013 Springer Science+Business Media New York.

引用

页码：30 / 36

页数：6

共 27 条

[1]

Barnes L., Eveson J., Reichart P., Sidransky D., Pathology and Genetics of Head and Neck Tumours, World Health Organization Classification of Tumours, (2005)

[2]

Gnepp D.R., Henley J.D., Simpson R.H.W., Eveson J., Salivary and Lacrimal glands, Diagnostic surgical pathology of the head and neck, pp. 413-562

[3]

Hunt J.L., An update on molecular diagnostics of squamous and salivary gland tumors of head and neck, Arch Pathol Lab Med, 135, pp. 602-609, (2011)

[4]

McCord C., Weinreb I., Perez-Ordonez B., Progress in salivary gland pathology: new entities and selected molecular features, Diagnostic Histopathol, 18, 6, pp. 253-260, (2012)

[5]

Skalova A., Vanecek T., Simpson R.H.W., Michal M., Molecular advances in salivary gland pathology and their practical application, Diagnostic Histopathol, 18, 9, pp. 388-396, (2012)

[6]

Skalova A., Vanecek T., Sima R., Laco J., Weinreb I., Perez-Ordonez B., Starek I., Geierova M., Simpson R.H.W., Passador-Santos F., Ryska A., Leivo I., Kinkor Z., Michal M., Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity, Am J Surg Pathol, 34, pp. 599-608, (2010)

[7]

Tognon C., Knezevich S.R., Huntsman D., Roskelley C.D., Melnyk N., Mathers J.A., Becker L., Carneiro F., MacPherson N., Horsman D., Poremba C., Sorensen P.H.B., Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma, Cancer Cell, 2, pp. 367-376, (2002)

[8]

Fehr A., Loning T., Stenman G., Mammary analogue secretory carcinoma of the salivary glands with ETV6-NTRK3 gene fusion, Am J Surg Pathol, 35, pp. 1600-1602, (2011)

[9]

Griffith C., Seethala R., Chiosea S.I., Mammary analogue secretory carcinoma: a new twist to the diagnostic dilemma of zymogen granule poor acinic cell carcinoma, Virchows Arch, 459, pp. 117-118, (2011)

[10]

Lei Y., Chiosea S.I., Re-evaluating historic cohort of salivary acinic cell carcinoma with new diagnostic tools, Head and Neck Pathol, 6, pp. 166-170, (2012)

← 1 2 3 →